Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03375203 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
NCT03375203 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 365 participants.
The verdict
NCT03375203, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
Study Summary
The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose administration in participants with insomnia disorder.
Interventions
- DRUG Placebo
- DRUG Zolpidem
- DRUG JNJ-42847922, 5 mg
- DRUG JNJ-42847922, 10 mg
- DRUG JNJ-42847922, 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2017-11-23 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03375203
The ClinicalTrials.gov registry entry for NCT03375203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03375203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03375203 about?
NCT03375203 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder". The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 day...
What is the current status of trial NCT03375203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2017-11-23. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT03375203?
The interventions under investigation include: Placebo (DRUG), Zolpidem (DRUG), JNJ-42847922, 5 mg (DRUG), JNJ-42847922, 10 mg (DRUG), JNJ-42847922, 20 mg (DRUG).
Who is sponsoring clinical trial NCT03375203?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.